Industry Overview - The novel immunotherapeutics market is rapidly growing, with a valuation of approximately USD 150-168 billion in 2025 and projected to exceed USD 300 billion by 2033-2035 [2] Company Focus: Aethlon Medical, Inc. - Aethlon Medical, Inc. is developing the Aethlon Hemopurifier®, an investigational device aimed at treating oncology and life-threatening viral infections [1][3] - The independent Data Safety Monitoring Board (DSMB) has completed a safety review of the second cohort in the ongoing clinical trial AEMD-2022-06, recommending advancement to the third cohort with no safety concerns noted [3][5] - The trial aims to assess the safety, feasibility, and optimal dosing of the Hemopurifier in patients with solid tumors receiving treatments that include Pembrolizumab or Nivolumab [4][6] - Enrollment for the third cohort is now open, with participants set to receive three Hemopurifier treatments over a one-week period [6] - The primary endpoint of the trial is to monitor adverse events and clinically significant changes in safety laboratory tests among Hemopurifier-treated patients [7] - The Hemopurifier is designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation, which are believed to contribute to metastasis and resistance to therapies [8] Clinical Development and Future Prospects - The DSMB's positive recommendation supports the safety profile of the Hemopurifier, allowing the trial to progress [6] - The study is expected to inform the design of a future efficacy and safety Premarket Approval (PMA) study required by regulatory authorities [7] - Aethlon Medical remains committed to advancing the Hemopurifier for oncology applications and will continue to provide updates as the clinical trial progresses [8]

Core Viewpoint - Tivic Health Systems, Inc. has appointed Michael K. Handley as the new Chief Executive Officer, effective immediately, indicating a strategic leadership change within the company [1] Company Summary - Tivic Health Systems, Inc. is identified as a late-stage immunotherapeutics company, suggesting its focus on advanced therapeutic solutions in the healthcare sector [1]

Core Viewpoint - Tivic Health® Systems, Inc. has announced a conference call to discuss the recent acquisition of CDMO assets, highlighting its strategic importance and potential benefits for the company [1] Group 1: Acquisition Details - The acquisition of certain CDMO assets was announced on December 11, 2025, and is expected to accelerate key strategic priorities for the company [1] - The conference call will address how this acquisition impacts development and commercialization timelines [1] Group 2: Future Prospects - The management will discuss near-term potential benefits resulting from the acquisition during the conference call [1]

Core Insights - Tivic Health® Systems, Inc. is advancing its strategic transformation and biologics pipeline, focusing on its lead product candidate, Entolimod, for acute radiation syndrome (ARS) [1] Financial Results - The company announced financial results for the third quarter and nine months ended September 30, 2025 [1] Business Update - Engagement with key government agencies has generated interest in Entolimod as a military medical countermeasure and stockpile drug [1]

Core Insights - Tivic Health Systems, Inc. has optimized key device and treatment parameters for ncVNS, enhancing its effectiveness through personalization [1] Company Developments - The company collaborated with The Feinstein Institutes for Medical Research at Northwell Health to conduct a study on ncVNS treatment [1] - Key parameters optimized include frequency, amplitude, electrode positioning, and duration of stimulation [1] Study Findings - Personalizing the frequency of ncVNS stimulation led to a 46% increase in heart rate variability, which was 8.9 times more effective than using a uniform frequency across all subjects [1] - The optimal ncVNS frequency varied between subjects and visits, highlighting the need for personalized stimulation parameters before each treatment [1] - Certain electrode placements and configurations were found to significantly impact heart rate variability, with some placements increasing it while others decreased it [1] - A duration of four minutes of ncVNS stimulation was sufficient to achieve a substantial increase in heart rate variability, proving more effective than twenty minutes of stimulation [1]